Summary
Sorafenib has been widely used to treat unresectable hepatocellular carcinoma (HCC) but most studies have been done in Child-Pugh A (CP-A) patients with well-preserved liver function. We evaluated the overall survival (OS) and tolerance to sorafenib in a large cohort of Child-Pugh B (CP-B) HCC patients as compared to CP-A HCC patients. We prospectively studied 130 patients with advanced HCC who started sorafenib between January 2011 and December 2015. Patients were classified as CP-A (n = 65) or CP-B (n = 65). The average OS for all 130 patients was 10 months. CP-A patients had a median survival rate significantly longer than CP-B patients: 12 months vs. 6 months. The OS found in our group of CP-B patients was 6.5 months, which is higher than that found in most studies done so far. When stratified, our CP-B patients had better OS than ever reported. The dose of the drug was interrupted due to adverse events (AEs) in 38 (29%) of the patients, of whom 20 (30%) were CP-A patients and 18 (28%) were CP-B patients. This real-life cohort of CP-B HCC patients treated with sorafenib had a higher survival than that described in the literature, with a satisfactory safety profile. Despite the high prevalence of severe AEs in CP-B patients, there were fewer treatment interruptions in this group, indicating that Child-Pugh B patients can tolerate treatment and may benefit from sorafenib.
Similar content being viewed by others
References
Torre LA, Bray F, Siegel RL et al (2015) Global cancer statistics, 2012. CA Cancer J Clin 65(2):87–108. https://doi.org/10.3322/caac.21262
Llovet JM, Fuster J, Bruix J (2004) The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma. Liver Transpl 10:S115–S120. https://doi.org/10.1002/lt.20034
Reig M, Gazzola A, Di Donato R, Bruix J (2014) Systemic treatment. Best Pract Res Clin Gastroenterol 28(5):921–935 https://www.ncbi.nlm.nih.gov/pubmed/25260318
Llovet JM, Ricci S, Mazzaferro V, Hilgard P et al (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378–390. https://doi.org/10.1056/NEJMoa0708857
Cheng AL, Kang YK, Chen Z et al (2009) Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomized, double-blind, placebo- controlled trial. Lancet Oncol 10:25–34. https://doi.org/10.1016/S1470-2045(08)70285-7
European Association For The Study Of The Liver; European Organisation ForResearch And Treatment Of Cancer (2012) EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 56(4):908–943. https://doi.org/10.1016/j.jhep.2011.12.001
Bruix J, Sherman M (2011) American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology 53(3):1020–1022 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3084991
Oken MM, Creech RH, Tormey DC et al (1982) Toxicity and response criteria of the eastern cooperative oncology group. Am J Clin Oncol 5:649–655
Pugh RN, Murray-Lyon IM, Dawson JL et al (1973) Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 60(8):646–649
Lencioni R, Llovet JM (2010) Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 30(1):052–060
U.S. Department of health and human services. National Institutes of Health. National Cancer Institute. Common Terminology Criteria for Adverse Events v4.0 (CTCAE). (2009) [cited 2018 Jun 1]; Available from: https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03/Archive/CTCAE_4.0_2009-05-29_QuickReference_8.5x11.pdf
Wada Y, Takami Y, Tateishi M et al (2016) The efficacy of continued sorafenib treatment after radiologic confirmation of progressive disease in patients with advanced hepatocellular carcinoma. PLoS One 11(1):e0146456. https://doi.org/10.1371/journal.pone.0146456
Marrero JA, Kudo M, Venook AP et al (2016) Observationl registry of Sorafenib use in clinical practice across child-Pugh subgroups: the GIDEON study. J Hepatol 65:1140–1147. https://doi.org/10.1016/j.jhep.2016.07.020
Abou-Alfa GK, Amadori D, Santoro A et al (2008) Is sorafenib (S) safe and effective in patients (pts) with hepatocellular carcinoma (HCC) and child-Pugh B (CPB) cirrhosis? J Clin Oncol 26(15_suppl):4518. https://doi.org/10.1200/jco.2008.26.15_suppl.4518
Da Fonseca LG, Sousa RB, Bento ASA et al (2015) Safety and efficacy of sorafenib in patients with child-Pugh B advanced hepatocellular carcinoma. Mol Clin Oncol 3:793–796. https://doi.org/10.3892/mco.2015.536
Chiu J, Tang YF, Yao T et al (2012) The use of single-agent Sorafenib in the treatment of advanced hepatocellular carcinoma patients with underlying child-Pugh B liver cirrhosis. A retrospective analysis of efficacy, safety, and survival benefits. Cancer 118(21):5293–5301. https://doi.org/10.1002/cncr.27543
Ogasawara S, Chiba T, Ooka Y et al (2015) Sorafenib treatment in child-Pugh a and B patients with advanced hepatocellular carcinoma: safety, efficacy and prognostic factors. Investig New Drugs 33:729–739. https://doi.org/10.1007/s10637-015-0237-3
Abou-Alfa GK, Amadori D, Santoro A et al (2011) Safety and efficacy of Sorafenib in patients with hepatocellular carcinoma (HCC) and child-Pugh a versus B cirrhosis. Gastrointest Cancer Res 4(2):40–44
Federico A, Orditura M, Cotticelli G et al (2015) Safety and efficacy of Sorafenib in patients with advanced hepatocellular carcinoma and child-Pugh a or B cirrhosis. Oncol Lett 9:1628–1632. https://doi.org/10.3892/ol.2015.2960
Pinter M, Sieghart W, Graziadel I et al (2009) Sorafenib in Unresectable hepatocellular carcinoma from mild to advanced stage liver cirrhosis. Oncologist 14:70–76. https://doi.org/10.1634/theoncologist.2008-0191
Hollebecque A, Cattan S, Romano O et al (2011) Safety and efficacy of Sorafenib in hepatocellular carcinoma: the impact of the child-Pugh score. Aliment Pharmacol Ther 34:1193–1201. https://doi.org/10.1111/j.1365-2036.2011.04860.x
Pressiani T, Boni C, Rimassa L et al (2013) Sorafenib in patients with child-Pugh class a and B advanced hepatocellular carcinoma: a prospective feasibility analysis. Ann Oncol 24(2):406–411. https://doi.org/10.1093/annonc/mds343
Pinter M, Sieghart W, Hucke F et al (2011) Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib. Aliment Pharmacol Ther 34:949–959. https://doi.org/10.1111/j.1365-2036.2011.04823.x
Koschny R, Gotthardt D, Koehler C et al (2013) Diarrhea is a positive outcome predictor for Sorafenib treatment of advanced hepatocellular carcinoma. Oncology 84:6–13. https://doi.org/10.1159/000342425
Reig M, Lope CR, Llarch N et al (2013) Dermatologic adverse events within the first 60 days of sorafenib treatment are associated with better overall survival (OS) in patients with hepatocellular carcinoma (HCC). J Hepatol 58(Suppl. 1):S63–S227. https://doi.org/10.1016/S0168-8278(13)60269-X https://www.journal-of-hepatology.eu/article/S0168-8278(13)60269-X/abstract
Raoul J, Adhoute X, Gilabert M, Edeline J (2016) How to assess the efficacy or failure of targeted therapy: deciding when to stop Sorafenib in hepatocellular carcinoma. World J Hepatol 8(35):1541–1546. https://doi.org/10.4254/wjh.v8.i35.1541
Colagrande S, Regini F, Taliani GG et al (2015) Advanced hepatocellular carcinoma and Sorafenib: diagnosis, indications, clinical and radiological Folllow-up. World J Hepatol 7(8):1041–1053. https://doi.org/10.4254/wjh.v7.i8.1041
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
All authors declare that they have no conflicts of interest.
Ethical approval
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent
The study protocol was approved by the local Ethics Committee and all patients signed a consent form.
Rights and permissions
About this article
Cite this article
Leal, C.R.G., Magalhães, C., Barbosa, D. et al. Survival and tolerance to sorafenib in Child-Pugh B patients with hepatocellular carcinoma: a prospective study. Invest New Drugs 36, 911–918 (2018). https://doi.org/10.1007/s10637-018-0621-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10637-018-0621-x